IBD & Intestinal Disorders
News
Many young people stop ulcerative colitis maintenance treatment, risking relapse
Globally, the incidence of UC is increasing fastest in younger populations. It’s estimated that up to 30% of individuals with UC are diagnosed in...
News
Race and ethnicity loom large in CRC screening
Disparities can be seen in everything from choice of test to bowel prep, according to a review.
News
Sucralose damages DNA, linked to leaky gut: Study
The FDA says sucralose is safe, describing it as 600 times sweeter than table sugar and used in “baked goods, beverages, chewing gum, gelatins,...
News
Gut microbiome may guide personalized heart failure therapy
Understanding the gut microbiome and how it may affect development and treatment of heart failure could lead to a more personalized approach to...
News
Clinical Practice Update: Alpha-gal syndrome often causes GI issues without anaphylaxis, skin changes
“It is important for gastroenterologists to be aware of this condition and to be capable of diagnosing and treating it in a timely manner.”
News from the FDA/CDC
FDA approves new formulation of Hyrimoz adalimumab biosimilar
The agency approved a higher-concentration formulation of Hyrimoz for its previous indications, including rheumatoid arthritis and psoriasis.
Conference Coverage
Upadacitinib shows positive endoscopic outcomes in Crohn’s disease at 1 year
“The absolute magnitude of the finding was unanticipated – a greater treatment effect than might be anticipated for these outcomes compared with...
News
Ulcerative colitis cases projected to top 2 million in eight countries by 2031
GlobalData epidemiologists attribute the predicted increases in UC prevalence and incidence to changes in population dynamics in each country.
News
COVID raises risk for long-term GI complications
“Are patients attributing their symptoms to COVID, or is COVID itself creating a background of inflammation or changes in the nerves that are...
Conference Coverage
IBD: More patients on vedolizumab vs. anti-TNFs at 2 years
Vedolizumab showed a higher overall 1- and 2-year persistence of use, compared with two anti–tumor necrosis factor inhibitors in both Crohn’s...